UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

Proceedings of the National Academy of Sciences - PNAS, 2006-07, Vol.103 (28), p.10660-10665

2006

Volltextzugriff (PDF)

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (6), p.1888-1893

2006

Volltextzugriff (PDF)

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (3), p.779-789

2012

Volltextzugriff (PDF)

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

Molecular therapy, 2014-02, Vol.22 (2), p.359-370

2014

Volltextzugriff (PDF)

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

Cancer research (Chicago, Ill.), 2005-03, Vol.65 (5), p.1918-1924

2005

Volltextzugriff (PDF)

Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis

The Journal of biological chemistry, 2004-12, Vol.279 (51), p.53015-53022

2004

Volltextzugriff (PDF)

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Molecular cancer, 2011-05, Vol.10 (1), p.49-49, Article 49

2011

Volltextzugriff (PDF)

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

Cell cycle (Georgetown, Tex.), 2008-06, Vol.7 (11), p.1604-1612

2008

Volltextzugriff (PDF)

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy

Cell cycle (Georgetown, Tex.), 2010-08, Vol.9 (16), p.3384-3395

2010

Volltextzugriff (PDF)

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2644-2658

2006

Volltextzugriff (PDF)

A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage

Cancer research (Chicago, Ill.), 2008-02, Vol.68 (4), p.1162-1169

2008

Volltextzugriff (PDF)

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2006-04, Vol.16 (7), p.1775-1779

2006

Volltextzugriff (PDF)

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Cancer research (Chicago, Ill.), 2011-08, Vol.71 (16), p.5535-5545

2011

Volltextzugriff (PDF)

Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility

Bioorganic & medicinal chemistry letters, 2006-04, Vol.16 (7), p.1780-1783

2006

Volltextzugriff (PDF)

Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts

Anticancer research, 2009-01, Vol.29 (1), p.91-98

2009

Volltextzugriff (PDF)

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (13), p.5518-5527

2010

Volltextzugriff (PDF)

Therapeutic intervention and signaling

Current opinion in cell biology, 1998-04, Vol.10 (2), p.284-288

1998

Volltextzugriff (PDF)

Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-negative Breast Adenocarcinoma Xenograft Model

Anticancer research, 2007-07, Vol.27 (4B), p.2279-2287

2007

Volltextzugriff (PDF)

Biochemical and Structural Characterization of a Novel Class of Inhibitors of the Type 1 Insulin-like Growth Factor and Insulin Receptor Kinases

Biochemistry (Easton), 2005-07, Vol.44 (27), p.9430-9440

2005

Volltextzugriff (PDF)

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Clinical cancer research, 2014-07, Vol.20 (14), p.3742-3752

2014

Volltextzugriff (PDF)

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (4), p.969-978

2012

Volltextzugriff (PDF)

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7672-7680

2009

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(80)
Dissertationen
(1)

Sprache

Englisch
(81)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(54)
Humans
(46)
Biological And Medical Sciences
(35)
Animals
(34)
Mice
(26)
Medical Sciences
(25)
Oncology
(22)
Biochemistry & Molecular Biology
(21)
Pharmacology. Drug Treatments
(21)
Antineoplastic Agents
(19)
Cell Line, Tumor
(19)
Tumors
(16)
Mice, Nude
(15)
Xenograft Model Antitumor Assays
(15)
Female
(13)
Molecular Sequence Data
(12)
Amino Acid Sequence
(11)
Fundamental And Applied Biological Sciences. Psychology
(10)
Pharmacology & Pharmacy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility

Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Therapeutic intervention and signaling

3-Aminopyrrolidinone Farnesyltransferase Inhibitors: Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-negative Breast Adenocarcinoma Xenograft Model

Biochemical and Structural Characterization of a Novel Class of Inhibitors of the Type 1 Insulin-like Growth Factor and Insulin Receptor Kinases

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Design and Biological Activity of (S)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency

Suchergebnisse filtern